The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Open accessAbstract
BACKGROUND: Alzheimer's disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological endpoint. However, Alzheimer's disease drug trials do not account for the heterogeneity of the disease in trial design, impeding development of effective drugs. DISCUSSION: Alzheimer's disease drug trials commonly have wide inclusion criteria that subsume multiple subtypes of the condition, with varying genotypes, phenotypes, and clinical courses. The outcome variables used in many trials may not be sensitive for the particular disease subtype and trials may not follow patients for the appropriate length of time necessary for the subtype of disease. Methods of stratifying treatment trial design to account for disease heterogeneity using algorithms incorporating demographics, neuroimaging, genetics, and clinical phenotypes, as well as more tailored outcome measures, are proposed to allow for personalized, precision medicine in Alzheimer's disease therapeutics development. Approaching Alzheimer's disease as a heterogenous disorder will likely improve yield in the search for effective treatments for the condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterogeneity, or more specifically, the diverse cell populations within the diseased tissue, is the leading cause of treatment failure for many complex diseases, such as cancers1, Alzheimer’s disease2, stroke3, and coronavirus disease 2019 (COVID-19)4, etc., as well as a major obstacle to successful precision medicine5–7.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · cited 1×
“The advent of tau neuroimaging has led to the realization that patients with Alzheimer’s disease who have similar amyloid loads may differ clinically based on the location of tau deposits [10].”
BackgroundMurray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · cited 1×
“In an autopsy series of 889 patients with Alzheimer’s disease, neurofibrillary tangle location distinguished three types with dramatically different rates of deterioration, from five points annually on the MMSE to just a point a year [3].”
BackgroundDesikan, R. S., Fan, C. C., Wang, Y., Schork, A. J., Cabral, H. J., Cupples, L. A., Thompson, W. K., Besser, L., Kukull, W. A., Holland, D., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002258 · Cited by 395 · cited 1×
“Additional stratification, either by known mutations in early-onset patients or using a polygenic hazard ratio in late-onset patients, obtained using disease-associated single nucleotide polymorphisms and APOE status, may further refine populations for therapeutic trials [15].”
BackgroundAlzheimer's disease, a multifactorial disorder seeking multitherapies
Iqbal, K., & Grundke‐Iqbal, I. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.04.006 · Cited by 255 · cited 1×
“Another study found five different subgroups of sporadic Alzheimer’s disease with different clinical profiles based on CSF levels of AB1–42, tau, and ubiquitin [9].”
Dubois, B., Epelbaum, S., Nyasse, F., Bakardjian, H., Gagliardi, G., Uspenskaya, O., Houot, M., Lista, S., Cacciamani, F., Potier, M.-C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30029-2 · Cited by 237
Ferreira, D., Verhagen, C., Hernández-Cabrera, J. A., Cavallin, L., Guo, C.-J., Ekman, U., Muehlboeck, J.-S., Simmons, A., Barroso, J., Wahlund, L.-O., et al. (2017) · Scientific Reports · doi:10.1038/srep46263 · Cited by 226 · cited 2×
“Y’s form, with language impairment, being more aggressive [4].”
BackgroundRoberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223
The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis
Scheltens, N. M. E., Galindo‐Garre, F., Pijnenburg, Y. A. L., van der Vlies, A. E., Smits, L. L., Koene, T., Teunissen, C. E., Barkhof, F., Wattjes, M. P., Scheltens, P., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309582 · Cited by 135
Self-citationAlzheimer Disease: Clinical and Biological Heterogeneity
Friedland, R. P., Koss, E., Haxby, J. V., Grady, C. L., Luxenberg, J. S., Schapiro, M. B., & Kaye, J. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-298 · Cited by 103
High Degree of Heterogeneity in Alzheimer's Disease Progression Patterns
Komarova, N. L., & Thalhauser, C. J. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002251 · Cited by 98
Cited by
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
Self-citationDuara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
“Greater effort in accounting for this heterogeneity should yield better outcomes in AD clinical trials [213].”
BackgroundJoie, R. L., Visani, A. V., Lesman‐Segev, O. H., Baker, S. L., Edwards, L., Iaccarino, L., Soleimani‐Meigooni, D. N., Mellinger, T. J., Janabi, M., Miller, Z., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011270 · Cited by 144
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 91
Metadata
- Authors
- Devi, G., & Scheltens, P.
- Affiliations
- Northwell Health (US)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Devi, Gayatri
- Venue
- Alzheimer's Research & Therapy
- Published
- 2018-12
- Volume
- 10
- Issue
- 1
- Pages
- 122-122
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC6300886
- OpenAlex
- W2904462606
- Cited by
- 102
- References
- 16
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 20 · 2020: 8 · 2019: 4
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- Alzheimer's disease, disease heterogeneity, clinical trial design, disease subtypes, phenotypes, genotypes, personalized medicine, precision medicine, outcome measures, neuroimaging, drug development
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heterogeneity of Alzheimer’s disease: consequence for drug trials? https://app.cochat.ai/papers/10.1186/s13195-018-0455-y
- The paper
- Devi, G., & Scheltens, P. (2018). Heterogeneity of Alzheimer’s disease: consequence for drug trials? Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-018-0455-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.